Modifies provisions relating to gender transition procedures
Summary
HB 1038 repeals and replaces Missouri’s existing section 191.1720 with a new section titled the “Missouri Save Adolescents from Experimentation (SAFE) Act.” The bill prohibits healthcare providers from knowingly performing gender transition surgery on anyone under 18. It also prohibits prescribing or administering cross-sex hormones or puberty-blocking drugs to minors for the purpose of gender transition, with a limited grandfathering provision for minors who were already receiving such treatment before August 28, 2023, through March 1, 2026.
The bill defines a number of terms, including biological sex, gender transition, gender transition surgery, cross-sex hormones, and puberty-blocking drugs. It creates enforcement mechanisms by treating violations as unprofessional conduct subject to license revocation, and it also creates a private right of action allowing injured individuals to sue healthcare providers. The bill includes extended limitations periods, damages provisions, attorney’s fees, and restrictions on confidentiality in settlements, while also preserving First Amendment speech protections and carving out exceptions for certain disorders of sex development, treatment of complications, and emergency medical care.
Impact
HB 1038 would significantly change Missouri law governing medical treatment for minors by restricting gender-affirming care for individuals under 18 and by exposing providers to professional discipline and civil liability for violations. It would amend the state’s health and licensing framework, affect healthcare providers and medical boards, and create new statutory causes of action and damages rules that override chapter 538 for these claims. The bill also includes specific exceptions for intersex or medically verifiable disorders of sex development, treatment of complications from prior care, and emergency procedures.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the available context suggests the bill is framed in strongly supportive terms by its sponsor and proponents, using the title “SAFE Act” and emphasizing protection of minors. The overall sentiment in the text is restrictive and precautionary toward gender transition procedures for minors. No recorded vote history or committee discussion is available here to show opposition or amendment activity, but the subject matter is likely to be politically and medically contentious.
Contention
The main points of contention are likely to be whether minors should be allowed access to gender-affirming medical treatment, whether the state should prohibit or limit treatment decisions made by families and physicians, and whether the bill’s civil liability and license-revocation provisions are appropriate. Opponents would likely focus on the ban on puberty blockers and cross-sex hormones, the private right of action, and the long limitations period and damages provisions; supporters would likely argue the bill protects children from irreversible medical interventions. Additional controversy may arise over the bill’s exceptions for disorders of sex development and emergency care, and over whether the definitions are medically accurate or overly broad.